Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia
- 14 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (2), 585-594
- https://doi.org/10.1038/s41375-020-0863-4
Abstract
HLA-matching largely contributes to unrelated donor hematopoietic cell transplantation (UD-HCT) success but, due to the selective deletion of alloreactive T-cells, post-transplantation cyclophosphamide (PTCy) could modulate its negative impact on outcomes. We retrospectively compared acute leukemia patients receiving 10/10 or 9/10 HLA allele-matched UD-HCT with PTCy-GvHD prophylaxis between 2010 and 2017, reported to EBMT registry. The 100-day incidence of grade ≥2 and grade ≥3 aGvHD were comparable for 10/10 and 9/10 UD (28% versus 28%, p = 0.8 and 10% versus 8%, p = 0.5, respectively). The 2-year cGvHD and extensive cGvHD were similar between 10/10 and 9/10 UD (35% versus 44%, p = 0.2 and 21% versus 20%, p = 0.6, respectively). The 2-year nonrelapse mortality was 20% after 10/10 and 16% after 9/10 UD-HCT (p = 0.1). Relapse incidence at 2-year was 24% for 10/10 and 28% for 9/10 UD-HCT (p = 0.4). Leukemia-free survival at 2-year was the same for 10/10 and 9/10 UD (56 and 56%, p = 0.6, respectively), with comparable overall survival (62 and 59%, p = 0.9, respectively). Multivariate analysis showed no effect of HLA-matching on outcomes. An advanced disease status and patient disability remained the most important factors portending a worse survival. PTCy could alleviate the detrimental effect of HLA-allele mismatching in UD-HCT, potentially expanding the donor pool for acute leukemia patients.Keywords
This publication has 57 references indexed in Scilit:
- Recipient/donor HLA and CMV matching in recipients of T-cell-depleted unrelated donor haematopoietic cell transplantsBone Marrow Transplantation, 2017
- The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancyBlood, 2016
- High HLA-DP Expression and Graft-versus-Host DiseaseThe New England Journal of Medicine, 2015
- Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategyHaematologica, 2015
- HLA-C expression levels define permissible mismatches in hematopoietic cell transplantationBlood, 2014
- HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. RegistryThe New England Journal of Medicine, 2014
- Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practiceBone Marrow Transplantation, 2013
- Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective studyThe Lancet Oncology, 2012
- High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantationBlood, 2007
- Marrow Transplantation for Malignant DiseaseThe American Journal of the Medical Sciences, 1987